New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:02 EDTMYGNPiper sees negative BRACA decisions as isolated for Myriad Genetics
Piper Jaffray says its work suggests "little negative provider updates" for Myriad Genetics (MYGN) beyond Horizon BCBS recently naming LabCorp (LH) as its in-patient BRCA test provider and Health Plus's update urging the discontinuation of Myriad for BRCA testing. The firm believes recent negative BRACAnalysis decisions are isolated and keeps an Overweight rating on Myriad with a $44 price target.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
15:46 EDTMYGNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 20, 2015
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.
January 15, 2015
07:59 EDTMYGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 12, 2015
07:17 EDTMYGNJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use